Front Cover: A Series of 2‐((1‐Phenyl‐1H‐imidazol‐5‐yl)methyl)‐1H‐indoles as Indoleamine 2,3‐Dioxygenase 1 (IDO1) Inhibitors (ChemMedChem 14/2021)

The Front Cover illustrates the ‘molecule to mind’ structural hierarchy of pathology and symptoms arising from Alzheimer's disease. Although Alzheimer's presents as a disorder of thought, memory, and cognition, it is a disease that we seek to treat not at the cellular level, but at the mol...

Full description

Saved in:
Bibliographic Details
Published in:ChemMedChem 2021-07, Vol.16 (14), p.2157-2157
Main Authors: Zheng, Yong, Stafford, Paul M., Stover, Kurt R., Mohan, Darapaneni Chandra, Gupta, Mayuri, Keske, Eric C., Schiavini, Paolo, Villar, Laura, Wu, Fan, Kreft, Alexander, Thomas, Kiersten, Raaphorst, Elana, Pasangulapati, Jagadeesh P., Alla, Siva R., Sharma, Simmi, Mittapalli, Ramana R., Sagamanova, Irina, Johnson, Shea L., Reed, Mark A., Weaver, Donald F.
Format: Article
Language:English
Subjects:
computational modelling
IDO1 inhibitors
imidazole
structure-activity relationship
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Front Cover illustrates the ‘molecule to mind’ structural hierarchy of pathology and symptoms arising from Alzheimer's disease. Although Alzheimer's presents as a disorder of thought, memory, and cognition, it is a disease that we seek to treat not at the cellular level, but at the molecular level. Given that the brain is the most complex structure in the universe, and that Alzheimer's is the most complex disease of brain, the search for new treatments must address all possible avenues. The brain's immune system is an important emerging druggable target; we describe our identification of indoleamine 2,3‐dixoygenase inhibitors as putative disease modifying therapies for Alzheimer's. More information can be found in the Communication by Donald F. Weaver et al.
ISSN:1860-7179
1860-7187
DOI:10.1002/cmdc.202100466